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Nearly every pregnant woman has faced a decision about whether or not to take a 
medication during pregnancy, ranging from over-the-counter antacids for gastroesophageal 
reflux to prescription medications for life-threatening chronic conditions. Medication use is 
common during pregnancy; estimates of the prevalence of use during pregnancy of at least 
one prescription medication range from less than 30% to over 90% of women [1,2]. The 
safety of use during pregnancy, however, is not always clear because the majority of 
medications lack sufficient data to appropriately evaluate their teratogenicity until decades 
after initial marketing [3]. Both acute and chronic medical conditions that are relatively 
common in reproductive aged women can require treatment during pregnancy, such as 
infections, cough and cold symptoms, allergies, depression, asthma, thyroid disorders, 
diabetes, and migraines. However, depending on the timing of pregnancy recognition, 
women may or may not be aware of their pregnancy when taking medications for these 
conditions. Medication use during pregnancy impacts two patients, the woman and her 
developing fetus, and healthcare providers and women are frequently asked to make critical 
clinical treatment decisions in the absence of sufficient information about the likely impact 
of the medication on both patients.
Currently there are resources that provide an evaluation of the teratogenic risk associated 
with specific medications, but these resources are not widely available to women and their 
healthcare providers as most are available only by subscriptions [4]. Instead, many 
healthcare providers rely on resources, such as the Physicians’ Desk Reference (PDR) and 
the Food and Drug Administration (FDA) pregnancy categorization as noted in the product 
label, that do not adequately inform the best medication choice during pregnancy [5,6]. 
Professional guidance has been developed for some specific conditions or medication types, 
such as the Committee Opinion from the American College of Obstetricians and 
Gynecologists on the use of certain antibiotics during pregnancy, the American Academy of 
Neurology and American Epilepsy Society’s guidelines on the management of epilepsy 
during pregnancy, and the guidelines for the treatment of human immunodeficiency virus 
Financial disclosure: The authors have no conflicts of interest to disclose.
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of 
the Centers for Disease Control and Prevention.
HHS Public Access
Author manuscript
Expert Rev Clin Pharmacol. Author manuscript; available in PMC 2015 August 07.
Published in final edited form as:













(HIV) in pregnancy developed by the HHS Panel on Treatment of HIV-Infected Pregnant 
Women and Prevention of Perinatal Transmission [7,8][101]. However, there is no 
systematic and ongoing approach to the development of such guidance for most maternal 
conditions, and therefore a need for both development of guidance and dissemination to 
appropriate providers.
Safer medication use during pregnancy also means taking steps to avoid unnecessary 
exposure to known teratogens in pregnancy. While the teratogenicity of many medications is 
unknown, there are some medications in use that have been clearly identified as human 
teratogens such as valproic acid and isotretinoin [8,9]. And, for some known teratogens, use 
is relatively high among reproductive aged women [10]. This is particularly concerning 
given the prevalence of unintended pregnancies in the U.S. of 49% [11]. Moreover, most 
healthcare providers prescribing potentially teratogenic medications in outpatient settings do 
not provide contraceptive counseling when these medications are prescribed [12].
Some healthcare providers and internet sites provide lists of medications reported to be 
“safe” for use during pregnancy; however, there are many inconsistencies between the 
available lists, and the evidence base for labeling many of the medications as “safe” is 
inadequate [13]. Many sites lack information on how the lists were developed or appropriate 
citations to peer-reviewed literature. It is unknown whether these “safe” lists actually 
increase the use of medications during pregnancy, including potentially the use of some 
medications not really necessary to treat the maternal condition. Most significantly, such 
lists have the potential to shortcut opportunities for important discussion between a woman 
and her healthcare provider about the necessity of specific medications during pregnancy 
given the patient’s full medical profile.
The commonly held assumption of the safety of medications is in contrast to the usual 
concerns about x-ray exposure in pregnancy. There are little data to support the 
teratogenicity of diagnostic x-rays at the typical exposure levels [14]. Nonetheless, there is 
great concern among pregnant women about potential exposure to radiation from diagnostic 
tests, and reproductive aged women needing x-rays are typically screened for pregnancy in 
some manner by healthcare providers before diagnostic radiography. There are far less 
systematic approaches in place to consider the possibility of a current or future pregnancy 
when making medication treatment decisions. There is a pressing need to increase awareness 
of medication use in pregnancy as an important public health issue, and to encourage more 
evidence-based decision making around medication use. Before prescribing medication to 
reproductive aged women, a conversation about pregnancy, pregnancy intention, and 
contraception is warranted to adequately assess the true need, and ensure avoidance of 
unnecessary exposures during pregnancy.
Addressing safer use of medication during pregnancy requires a partnership between public 
health and clinical medicine with a common goal of improving the health of women and 
their fetuses/infants. For many relatively common maternal conditions, there is a need to 
better understand the safety or risk of using specific medication alternatives during 
pregnancy. While improving the information available for all medications that might be used 
in pregnancy would be ideal, priority should be given to those conditions and medications 
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for which more appropriate use is likely to have the greatest public health impact. Some key 
factors to consider in assessing the potential public health impact include the prevalence of 
the maternal condition among reproductive aged women, the prevalence of medication use 
for the maternal condition under consideration, the severity of the maternal condition, and 
the anticipated necessity of medication for appropriate treatment of the condition. Suspicion 
of adverse fetal effects based on case reports or animal data might also be considered in 
assessing the likely public health impact of prioritizing a particular condition.
For example, about 11% of US reproductive aged women reported a major depressive 
episode within the past 12 months; prescription medication treatment to manage the 
condition in women with a recent major depressive episode was reported by about 40% of 
pregnant women and 47% of non-pregnant reproductive aged women [15]. There are several 
medication options available, and the fetal risk might vary between these options. 
Furthermore, stopping antidepressant medications during pregnancy is typically not a 
reasonable option for many women given the necessity of this treatment for maternal health 
[16]. Similarly, an estimated 8–10% of US reproductive aged women and 8–9% of pregnant 
women have a current diagnosis of asthma [17]. Although 88% of pregnant women with 
current asthma reported symptoms during pregnancy, 41% reported no use of asthma 
medication during pregnancy [17]. Better data on safety or risk of specific asthma 
medication options during pregnancy could help optimize management of this potentially 
serious medical condition. However, with no “gold standard” information source to consult 
regarding treatment decisions for either of these relatively common conditions, clinical 
uncertainty exists, leading to significant variation in clinical care.
Developing and widely disseminating appropriate guidance for women and their healthcare 
providers to consider in making medication choices could make a significant positive public 
health impact. There is the potential to reduce the risk to the fetus by shifting clinical 
practice towards medications with a lower fetal risk profile, as well as improve the health of 
women during pregnancy and in their reproductive years by better informing clinical 
decisions about treatment options for serious medical conditions. The Centers for Disease 
Control and Prevention (CDC) has recently launched the TRxeating for Two Initiative as a 
key step towards safer use of medication during pregnancy. A Task Force model similar to 
what has been used by the U.S. Preventive Services Task Force is being proposed as the 
approach to develop and disseminate appropriate evidence summaries assessing maternal, 
embryonic, and fetal effects of medications used during pregnancy, and would include an 
evaluation of both the quality and the strength of the evidence assessing these effects [102]. 
More information about CDC’s work on medications in pregnancy is available at 
www.cdc.gov/pregnancymedication. Safer medication use in pregnancy can be advanced 
with a public health – clinical partnership, and this approach has the potential to make an 
important, positive impact on the health of women and their children.
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